China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving another indication approval from the National Medical Products Administration (NMPA) for its tegileridine. The Category 1 drug is now approved to treat postoperative moderate to severe pain.
Drug Profile and Mechanism
Tegileridine is a μ opioid receptor (MOR)-biased small-molecule agonist. It was first approved in China in January of last year for moderate to severe pain after abdominal surgery, marking it as the first home-grown Category 1 opioid analgesic in the country. This new approval expands its application to postoperative pain management, addressing a significant unmet need in the treatment of postoperative pain.
Market Context and Competition
Trevena’s Olinvyk (oliceridine), a similar product approved in the US in 2020, was licensed by Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) and approved in China in May 2023. Hengrui’s tegileridine now joins this segment, offering a domestically developed option for postoperative pain treatment.-Fineline Info & Tech
Leave a Reply